

G V Ramesh Prasad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7936015/publications.pdf>

Version: 2024-02-01

97
papers

5,227
citations

136950

32
h-index

88630

70
g-index

98
all docs

98
docs citations

98
times ranked

6460
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	1.7	474
2	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	1.7	431
3	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	1.7	400
4	Meta-Analysis: Risk for Hypertension in Living Kidney Donors. Annals of Internal Medicine, 2006, 145, 185.	3.9	341
5	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	1.7	269
6	Psychosocial Health of Living Kidney Donors: A Systematic Review. American Journal of Transplantation, 2006, 6, 2965-2977.	4.7	235
7	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	1.7	221
8	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 "therapy. Canadian Journal of Cardiology, 2010, 26, 249-258.	1.7	191
9	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2012, 28, 270-287.	1.7	173
10	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I "blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2010, 26, 241-248.	1.7	170
11	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2013, 29, 528-542.	1.7	163
12	Reconstituted Aquaporin 1 Water Channels Transport CO ₂ across Membranes. Journal of Biological Chemistry, 1998, 273, 33123-33126.	3.4	152
13	Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation, 2004, 77, 399-402.	1.0	123
14	Metabolic syndrome and chronic kidney disease: Current status and future directions. World Journal of Nephrology, 2014, 3, 210.	2.0	118
15	Rhabdomyolysis due to red yeast rice (<i>Monascus purpureus</i>) in a renal transplant recipient. Transplantation, 2002, 74, 1200-1201.	1.0	108
16	Outcomes of Commercial Renal Transplantation: A Canadian Experience. Transplantation, 2006, 82, 1130-1135.	1.0	86
17	New-onset diabetes mellitus after kidney transplantation: Current status and future directions. World Journal of Diabetes, 2015, 6, 445.	3.5	86
18	Post-transplant dyslipidemia: Mechanisms, diagnosis and management. World Journal of Transplantation, 2016, 6, 125.	1.6	84

#	ARTICLE	IF	CITATIONS
19	Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. <i>Clinical Nephrology</i> , 2000, 53, 55-60.	0.7	58
20	Renal transplant recipient attitudes toward steroid use and steroid withdrawal. <i>Clinical Transplantation</i> , 2003, 17, 135-139.	1.6	55
21	Reduced Incidence of New-Onset Diabetes Mellitus after Renal Transplantation with 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors (Statins). <i>American Journal of Transplantation</i> , 2004, 4, 1897-1903.	4.7	55
22	Framingham Risk Score and Novel Cardiovascular Risk Factors Underpredict Major Adverse Cardiac Events in Kidney Transplant Recipients. <i>Transplantation</i> , 2011, 92, 183-189.	1.0	52
23	Accepting Kidneys from Older Living Donors: Impact on Transplant Recipient Outcomes. <i>American Journal of Transplantation</i> , 2011, 11, 743-750.	4.7	51
24	Bone and Mineral Metabolism and Fibroblast Growth Factor 23 Levels After Kidney Donation. <i>American Journal of Kidney Diseases</i> , 2012, 59, 761-769.	1.9	48
25	Gout After Living Kidney Donation: A Matched Cohort Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 925-932.	1.9	45
26	Financial Costs Incurred by Living Kidney Donors: A Prospective Cohort Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2847-2857.	6.1	45
27	Canadian Society of Transplantation and Canadian Society of Nephrology Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2010, 56, 219-246.	1.9	44
28	Association of Uric Acid With Inflammation, Progressive Renal Allograft Dysfunction and Post-Transplant Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2009, 103, 867-871.	1.6	42
29	Fracture Risk in Living Kidney Donors: A Matched Cohort Study. <i>American Journal of Kidney Diseases</i> , 2012, 59, 770-776.	1.9	40
30	Organ donation after cardiac death: donor and recipient outcomes after the first three years of the Ontario experience. <i>Canadian Journal of Anaesthesia</i> , 2011, 58, 599-605.	1.6	38
31	CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 23-33.	0.7	36
32	Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. <i>Kidney International</i> , 2003, 63, 360-364.	5.2	33
33	Duration of Living Kidney Transplant Donor Evaluations: Findings From 2 Multicenter Cohort Studies. <i>American Journal of Kidney Diseases</i> , 2018, 72, 483-498.	1.9	33
34	Acute dialysis risk in living kidney donors. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3291-3295.	0.7	32
35	Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD. <i>American Journal of Kidney Diseases</i> , 2014, 63, 869-887.	1.9	31
36	Gastrointestinal-Specific Patient-Reported Outcome Instruments Differentiate Between Renal Transplant Patients With or Without GI Complications. <i>Transplantation Proceedings</i> , 2005, 37, 846-849.	0.6	30

#	ARTICLE	IF	CITATIONS
37	Policy Statement of Canadian Society of Transplantation and Canadian Society of Nephrology on Organ Trafficking and Transplant Tourism. <i>Transplantation</i> , 2010, 90, 817-820.	1.0	28
38	A Prospective Observational Study of Changes in Renal Function and Cardiovascular Risk Following Living Kidney Donation. <i>Transplantation</i> , 2008, 86, 1315-1318.	1.0	26
39	Commercial kidney transplantation is an important risk factor in long-term kidney allograft survival. <i>Kidney International</i> , 2016, 89, 1119-1124.	5.2	24
40	Cardiovascular magnetic resonance left ventricular strain in end-stage renal disease patients after kidney transplantation. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2018, 20, 83.	3.3	24
41	A pilot study of reduced dose cyclosporine and corticosteroids to reduce new onset diabetes mellitus and acute rejection in kidney transplant recipients. <i>Transplantation Research</i> , 2013, 2, 1.	1.5	23
42	South Asian Ethnicity as a Risk Factor for Major Adverse Cardiovascular Events after Renal Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 204-211.	4.5	22
43	Screening for cardiovascular disease before kidney transplantation. <i>World Journal of Transplantation</i> , 2015, 5, 276.	1.6	22
44	Hypertension in dialysis and kidney transplant patients. <i>Canadian Journal of Cardiology</i> , 2009, 25, 309-314.	1.7	21
45	Metabolic syndrome definitions and components in predicting major adverse cardiovascular events after kidney transplantation. <i>Transplant International</i> , 2015, 28, 79-88.	1.6	20
46	Pre-transplantation glucose testing for predicting new-onset diabetes mellitus after renal transplantation. <i>Clinical Nephrology</i> , 2009, 71, 140-6.	0.7	20
47	Diltiazem use in tacrolimus-treated renal transplant recipients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2004, 29, 425-430.	1.5	19
48	Comparison of the effects of standard vs low-dose prolonged-release tacrolimus with or without ACEi/ARB on the histology and function of renal allografts. <i>American Journal of Transplantation</i> , 2019, 19, 1730-1744.	4.7	19
49	Minimal Change Disease in Association With Fire Coral (<i>Millepora</i> Species) Exposure. <i>American Journal of Kidney Diseases</i> , 2006, 47, e15-e16.	1.9	17
50	Perioperative Complications During Living Donor Nephrectomy: Results From a Multicenter Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811985771.	1.1	17
51	Safety and efficacy of prophylaxis for <i>Pneumocystis jirovecii</i> pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation. <i>BMC Infectious Diseases</i> , 2019, 19, 311.	2.9	17
52	Ambulatory blood pressure monitoring in solid organ transplantation. <i>Clinical Transplantation</i> , 2012, 26, 185-191.	1.6	16
53	Living kidney donor estimated glomerular filtration rate and recipient graft survival. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 188-195.	0.7	16
54	Nonreimbursed Costs Incurred by Living Kidney Donors: A Case Study From Ontario, Canada. <i>Transplantation</i> , 2019, 103, e164-e171.	1.0	16

#	ARTICLE	IF	CITATIONS
55	Outcomes of SARS-CoV-2 Infection in Unvaccinated Compared With Vaccinated Solid Organ Transplant Recipients: A Propensity Matched Cohort Study. <i>Transplantation</i> , 2022, 106, 1622-1628.	1.0	15
56	The role of dietary cations in the blood pressure of renal transplant recipients. <i>Clinical Transplantation</i> , 2006, 20, 37-42.	1.6	14
57	Understanding the sex disparity in living kidney donation. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 999-1004.	1.8	14
58	Determinants of Left Ventricular Characteristics Assessed by Cardiac Magnetic Resonance Imaging and Cardiovascular Biomarkers Related to Kidney Transplantation. <i>Canadian Journal of Kidney Health and Disease</i> , 2018, 5, 205435811880997.	1.1	13
59	Growth differentiation factor 15 is decreased by kidney transplantation. <i>Clinical Biochemistry</i> , 2019, 73, 57-61.	1.9	13
60	A prospective study of the physician effect on blood pressure in renal-transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 996-1000.	0.7	12
61	Type I membranoproliferative glomerulonephritis in an HIV-infected individual without hepatitis C co-infection. <i>Clinical Nephrology</i> , 2002, 57, 154-157.	0.7	12
62	A comparison of the extended-release and standard-release formulations of tacrolimus in de novo kidney transplant recipients: a 12-month outcome study. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 45-49.	2.9	11
63	Role of Magnetic Resonance Elastography as a Noninvasive Measurement Tool of Fibrosis in a Renal Allograft: A Case Report. <i>Transplantation Proceedings</i> , 2017, 49, 1555-1559.	0.6	11
64	Angiotensinogen M235T genotype predicts progression in chronic renal allograft dysfunction. <i>Transplantation</i> , 2003, 75, 209-216.	1.0	10
65	Twenty four-hour ambulatory blood pressure profiles 12 months post living kidney donation. <i>Transplant International</i> , 2010, 23, 771-776.	1.6	10
66	A RAND-Modified Delphi on Key Indicators to Measure the Efficiency of Living Kidney Donor Candidate Evaluations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1464-1473.	4.5	10
67	Microalbuminuria post-renal transplantation: relation to cardiovascular risk factors and C-reactive protein. <i>Clinical Transplantation</i> , 2009, 23, 313-320.	1.6	8
68	A Numerical Scale Comparison of Renal Transplant Recipient Experience with and Opinions about Calcineurin Inhibitors. <i>Nephron Clinical Practice</i> , 2004, 97, c35-c40.	2.3	7
69	The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients. <i>Transplantation Research</i> , 2016, 5, 2.	1.5	7
70	Serum Apolipoprotein B and A1 Concentrations Predict Late-Onset Posttransplant Diabetes Mellitus in Prevalent Adult Kidney Transplant Recipients. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811985053.	1.1	7
71	A quality of life comparison in cyclosporine- and tacrolimus-treated renal transplant recipients across Canada. <i>Journal of Nephrology</i> , 2010, 23, 274-81.	2.0	7
72	Death with graft function in elderly patients after cadaveric renal transplantation: Effect of waiting time. <i>Transplantation Proceedings</i> , 2004, 36, 2985-2987.	0.6	6

#	ARTICLE	IF	CITATIONS
73	Lower total and percent of high-molecular-weight adiponectin concentration in South Asian kidney transplant recipients. CKJ: Clinical Kidney Journal, 2012, 5, 124-129.	2.9	6
74	Enhancing clinical judgement in virtual care for complex chronic disease. Journal of Evaluation in Clinical Practice, 2021, 27, 677-683.	1.8	6
75	Retrospective Analysis of Tacrolimus Inpatient Variability as a Measure of Medication Adherence. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110217.	1.1	5
76	Pre-Transplant Left Ventricular Geometry and Major Adverse Cardiovascular Events After Kidney Transplantation. Annals of Transplantation, 2019, 24, 100-107.	0.9	5
77	Recurrence of type III membranoproliferative glomerulonephritis after renal transplantation. Clinical Nephrology, 2004, 61, 80.	0.7	5
78	Post-transplant outcomes in recipients of living donor kidneys and intended recipients of living donor kidneys. BMC Nephrology, 2022, 23, 97.	1.8	5
79	Can Peer Review Be Kinder? Supportive Peer Review: A Re-Commitment to Kindness and a Call to Action. Canadian Journal of Kidney Health and Disease, 2022, 9, 205435812210803.	1.1	5
80	Adiponectin in renal disease – a review of the evidence as a risk factor for cardiovascular and all-cause mortality. Critical Reviews in Clinical Laboratory Sciences, 2012, 49, 218-231.	6.1	4
81	The Impact of Total Gastrectomy on Pharmacokinetics in Kidney Transplant Immunosuppressive Drug Regimes. Transplantation, 2017, 101, 2213-2217.	1.0	4
82	Recent advances in new-onset diabetes mellitus after kidney transplantation. World Journal of Diabetes, 2021, 12, 541-555.	3.5	4
83	Diabetic nephropathy with concurrent hepatitis C virus infection related membranoproliferative glomerulonephritis. Clinical Nephrology, 1999, 51, 50-3.	0.7	4
84	Distinguishing internal property from external property in kidney transplantation. Journal of Evaluation in Clinical Practice, 2016, 22, 539-543.	1.8	3
85	Medical good luck and medical bad luck. Journal of Evaluation in Clinical Practice, 2020, 26, 465-470.	1.8	3
86	The First North American Experience Using Glycosorb Immunoabsorption Columns for Blood Groupâ€“Incompatible Kidney Transplantation. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812096258.	1.1	3
87	Evaluation of left atrial remodeling in kidney transplant patients using cardiac magnetic resonance imaging. Journal of Nephrology, 2021, 34, 851-859.	2.0	3
88	Cardiac MRI assessment of the right ventricle pre-and post-kidney transplant. International Journal of Cardiovascular Imaging, 2021, 37, 1757-1766.	1.5	3
89	Statin use and bone mineral density in renal transplant recipients. American Journal of Transplantation, 2003, 3, 1320-1.	4.7	3
90	How the creative use of analogies can shape medical practice. Journal of Evaluation in Clinical Practice, 2015, 21, 455-460.	1.8	2

#	ARTICLE	IF	CITATIONS
91	The Increase in Paraoxonase 1 Is Associated With Decrease in Left Ventricular Volume in Kidney Transplant Recipients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 763389.	2.4	2
92	A Clinical and Pathological Variant of Acute Transplant Glomerulopathy. <i>Case Reports in Pathology</i> , 2014, 2014, 1-5.	0.3	1
93	A moral dilemma argument against clinical trials of incentives for kidney donation. <i>Transplantation Research</i> , 2015, 4, 3.	1.5	1
94	Impact of Perioperative Complications on Living Kidney Donor Health-Related Quality of Life and Mental Health: Results From a Prospective Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110374.	1.1	1
95	Managing cardiovascular disease risk in South Asian kidney transplant recipients. <i>World Journal of Transplantation</i> , 2021, 11, 147-160.	1.6	1
96	Monitoring Kidney Dysfunction in Kugelberg-Welander Syndrome. <i>American Journal of Case Reports</i> , 2019, 20, 441-446.	0.8	1
97	Reduction in New-Onset Diabetes Mellitus after Renal Transplant with Erythropoietin-Stimulating Agents: A Retrospective Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2016, 3, 114.	1.1	0